Biochemotherapy for Metastatic Melanoma: A Clinical Practice Guideline
Author Information
Author(s): Verma S. MD, Petrella T. MD, Hamm C. MD, Bak K. BA, Charette M. MA
Primary Institution: Cancer Care Ontario Program in Evidence-based Care
Hypothesis
What is the role of biochemotherapy in the treatment of metastatic malignant melanoma?
Conclusion
Biochemotherapy is not recommended for the treatment of metastatic melanoma due to inconsistent results and high toxicity rates.
Supporting Evidence
- Biochemotherapy showed a higher response rate compared to chemotherapy.
- Quality of life significantly declined through the 5th treatment cycle with biochemotherapy.
- High toxicity rates were consistently reported across studies.
Takeaway
Doctors looked at how well a combination of chemotherapy and immunotherapy works for melanoma, but they found it can be too harmful and doesn't help enough.
Methodology
Evidence was selected and reviewed by members of the Melanoma Disease Site Group and methodologists, with external review from Ontario practitioners.
Potential Biases
Potential conflicts of interest disclosed by members of the Melanoma Disease Site Group.
Limitations
Inconsistent results of studies regarding benefits and high toxicity rates.
Participant Demographics
Adult patients with metastatic malignant melanoma.
Statistical Information
P-Value
p < 0.0001
Confidence Interval
95% confidence interval (1.24 to 1.87)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website